Skip to main content

Table 6 Results of network meta-analysis with adjustment for covariates; indacaterol 75μg versus alternative treatments at 12 weeks

From: Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis

 

Trough FEV1L

SGRQ total score

IPD

AD

IPD

AD

Difference (95%CrI)

Prob. better

Difference (95%CrI)

Prob. better

Difference (95%CrI)

Prob. better

Difference (95%CrI)

Prob. better

Tiotropium 18

0.00 (−0.05; 0.04)

44 %

−0.02 (−0.06; 0.01)

12 %

−1.42 (−3.84; 0.97)

88 %

−1.27 (−5.95; 3.74)

72 %

Salmeterol 50

0.02 (−0.03; 0.07)

79 %

0.00 (−0.04; 0.04)

53 %

0.28 (−2.35; 2.97)

42 %

−1.74 (−6.89; 3.54)

77 %

Formoterol 12

0.07 (0.02; 0.11)

>99 %

0.05 (0.01; 0.09)

99 %

−0.40 (−2.90; 2.07)

62 %

−0.38 (−4.99; 4.87)

57 %

  1. AD = aggregate data; CrI = 95% Credibility Interval; FEV1 = Forced expiratory volume in 1 second; IPD = Individual patient data; SGRQ = St. George’s Respiratory Questionnaire; IPD covariates: baseline value of outcome; % current smokers; reversibility to short-acting β2-agonists (SABA); reversibility to short-acting anticholinergic + covariate interactions with treatments.AD covariates: % current smokers; % severe or very severe COPD; % males; age.